New drug cocktail aims to beat myeloma

NCT ID NCT07560449

Not yet recruiting Disease control Sponsor: Qilu Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests a new drug called QLS4131, given under the skin, in combination with other medications for people with malignant plasma cell neoplasms like multiple myeloma. The study will compare different drug combinations to see which works best at shrinking tumors and achieving deep responses. About 162 participants will be enrolled to evaluate safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QLS4131 (a drug given under the skin) combined with QL2109, pomalidomide, lenalidomide, or dexamethasone
What this could lead to: If successful, this could offer a more effective combination therapy for multiple myeloma, potentially leading to deeper remissions.
What could go wrong: This is an early Phase 2 trial with a small number of participants. The combinations may cause side effects or fail to improve outcomes over existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT PLASMA CELL NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis plasma cell leukemia plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT PLASMA CELL NEOPLASMS

More trials for these conditions

Other studies related to the condition(s) this trial covers.